GlassScriptPhysician profile
Thanhan Mathews
NPI 1942811377
$3,370.51
in general payments reported to CMS, 2019-2025
18 companies · $837 in 2025
The $837 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $619 · 2023: $420 · 2024: $1,001 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $982.77 | 2021-2025 | Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $556.77 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $474.12 | 2024-2025 | Jardiance, Omvoh, Zepbound |
| Abbott Laboratories | $229.91 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $192.45 | 2025 | Repatha, Repatha, Otezla |
| Optinose US, INC. | $163.67 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.24 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $146.94 | 2024-2025 | Voquezna |
| Dexcom, INC. | $139.58 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $122.98 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $43.75 | 2022-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $39.46 | 2022-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Gilead Sciences, INC. | $29.13 | 2023 | |
| Hologic Sales and Service, LLC | $24.34 | 2025 | Aptima, Thinprep 2000 Processor |
| Kowa Pharmaceuticals America, INC. | $24.14 | 2024 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $19.64 | 2022-2023 | Nexplanon |
| Phadia US INC. | $16.71 | 2021 | |
| Seqirus USA INC | $14.91 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanhan Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.